Phase 1/2 Trial of S241656
Phase 1/2
554
about 5.2 years
18+
10 sites in AZ, CO, DC +7
What this study is about
This trial is testing a new medication called S241656 in people with certain types of cancer. The goal is to see if it's safe and how well it works when used alone or with other treatments. Participants will take the medication orally every 28 days until their cancer progresses, they experience too much side effects, or they stop participating in the trial.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cetuximab
- 2.Take FOLFIRI
- 3.Take FOLFOX6/FOLFOX7
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cetuximab, gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules), panitumumab
injection (Injection), infusion
Primary: Dose Escalation: Number of Adverse Events (AEs) and Serious Adverse Events (SAEs), Dose Optimization/Expansion: Objective response (OR)
Secondary: Dose Escalation/Expansion: Incidence and severity of treatment-emergent adverse events (TEAEs), Dose Escalation/Optimization/Expansion: Area under the plasma drug concentration-time curve (AUC) of S241656 and its metabolite S243796, Dose Escalation/Optimization/Expansion: Duration of response (DOR), Dose Escalation/Optimization/Expansion: Half-life (t1/2) of S241656 and its metabolite S243796, Dose Escalation/Optimization/Expansion: Maximum plasma concentration (Cmax) of S241656 and its metabolite S243796, Dose Escalation/Optimization/Expansion: Overall survival (OS), Dose Escalation/Optimization/Expansion: Progression-free Survival (PFS), Dose Escalation/Optimization/Expansion: Time of maximum plasma concentration (Tmax) of S241656 and its metabolite S243796
Oncology